Publications

Publications

337 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

Report | 06-05-2021

GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia

Zorginstituut Nederland has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product that is ...

Report | 04-05-2021

Advice on the clustering of combination products and ghost clusters in GVS

The Minister of Medical Care has asked Zorginstituut Nederland questions about the clustering of two categories of medicinal ...

Report | 04-05-2021

GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

Zorginstituut Nederland has completed its assessment whether elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ...

Report | 29-04-2021

GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

Zorginstituut Nederland has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in the Medicine ...

Report | 19-04-2021

GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis

Zorginstituut Nederland has completed its assessment whether crisaborole (Staquis®) is interchangeable with a product that is ...

Report | 15-04-2021

GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children

Zorginstituut Nederland has completed its assessment whether rivaroxaban (Xarelto®) 1 mg/ml suspension can be included in the ...

Report | 17-03-2021

Advice on a potential candidate for conditional inclusion of entrectinib (Rozlytrek®) for solid tumours with NTRK gene fusion

Zorginstituut Nederland recommends that entrectinib should be designated as a potential candidate for conditional inclusion. ...

Letter | 10-03-2021

Advice on a potential candidate for conditional inclusion of larotrectinib (Vitrakvi®) for solid tumours with NTRK gene fusion

Zorginstituut Nederland recommends that larotrectinib should be designated as a potential candidate for conditional inclusion. ...

Letter | 10-03-2021

GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups

Zorginstituut Nederland has completed its assessment whether 13-valent pneumococcal conjugate vaccine (PVC13; Prevenar13®) is ...

Report | 03-03-2021